secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-12-18T23:59:59+00:00
Accession:  0000950170-24-137922
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics appoints Samir R. Patel as permanent CEO, adds Abizer Gaslightwala to board
--------------------------------------------------------------------------------

- Dr. Samir R. Patel appointed CEO effective Dec 16, 2024; he served as interim CEO since May 2024.
- Abizer Gaslightwala appointed as Class A director effective Dec 16, 2024; term expires at 2025 AGM.
- Michael Grissinger resigned from board on Dec 16, 2024; no disagreement with company operations.
- Gaslightwala is SVP at Jazz Pharma, previously at Amgen and Pfizer; deemed independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024137922/0000950170-24-137922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024137922/aktx-20241212.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-137922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer